Academic Journal
Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification
| العنوان: | Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification |
|---|---|
| المؤلفون: | Cervera, N, Carbuccia, N, Mozziconacci, M, Adélaïde, A, Garnier, S, Guille, A, Murati, A, Chaffanet, M, Vey, V, Birnbaum, D., Gelsi-Boyer, V |
| المساهمون: | Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| المصدر: | ISSN: 2044-5385 ; Blood Cancer Journal ; https://hal.science/hal-01789525 ; Blood Cancer Journal, 2017, 7 (8), pp.e594. ⟨10.1038/bcj.2017.68⟩. |
| بيانات النشر: | HAL CCSD Nature Publishing Group |
| سنة النشر: | 2017 |
| المجموعة: | Aix-Marseille Université: HAL |
| مصطلحات موضوعية: | [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics |
| الوصف: | International audience ; Due to the lack of specific clinical and biological features, M6a-acute erythroid leukemia (M6a-AEL), defined as an erythroid/myeloid type of acute leukemia, is no longer a distinct entity in the last classification of myeloid neoplasms by the World Health Organization (WHO). 1 The diagnosis of M6a-AEL was previously made if a proliferation of erythroid precursors ⩾ 50% with a myeloblast count ⩾ 20% when counted as a percentage of non-erythroid cells, was found in the bone marrow. 2 In 2016, revision of the WHO classification, the denominator used for calculating the blasts percentage was changed from non-erythroid cells to all nucleated cells. Consequently, M6a-AELs are now either myelodysplastic syndromes (MDSs) if the percentage of myelo-blasts is ⩾ 20% of non-erythroid cells but o20% of all nucleated cells or acute myeloid leukemia (AML) if the percentage of myeloblasts is ⩾ 20% of all nucleated cells. As for any other AMLs prior therapy, recurring WHO cytogenetic abnormalities, and criteria for AML with myelodysplasia-related changes (AML-MRC) have to be taken into consideration for classification. By using targeted next-generation sequencing (tNGS) and array-comparative genomic hybridization (aCGH), we previously established a molecular classification of 40 M6a-AELs 3 in five classes (C) based on mutations in NPM1 (C1), transcription factors (C2), splicing factors and/or chromatin modifiers (C3), TP53 (C4) or neither (C5). This classification could help in prognosis stratifica-tion. We have here re-analyzed our M6a-AEL molecular data according to 2016 WHO classification and compared them to a previously published cohort of MDS. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | hal-01789525; https://hal.science/hal-01789525; https://hal.science/hal-01789525/document; https://hal.science/hal-01789525/file/Cervera_Blood_2017.pdf |
| DOI: | 10.1038/bcj.2017.68 |
| الاتاحة: | https://hal.science/hal-01789525 https://hal.science/hal-01789525/document https://hal.science/hal-01789525/file/Cervera_Blood_2017.pdf https://doi.org/10.1038/bcj.2017.68 |
| Rights: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.2BD2FAD8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/bcj.2017.68 |
|---|